GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition

“-Provides Further Evidence of Long-term Efficacy-

GW Pharmaceuticals, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces top-line results from a 12 month placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosis (MS).

The study results confirm the reassuring safety profile of Sativex and provide further evidence of long-term efficacy.”

More: http://finance.yahoo.com/news/gw-pharmaceuticals-announces-results-ms-060000735.html

Pot smoking may help relieve symptoms of MS – NBC News

“Smoking marijuana may improve some symptoms of multiple sclerosis, a new study suggests.

Patients with multiple sclerosis in the study had less muscle tightness, also called spasticity, and less pain after they smoked marijuana, compared with after they took a placebo…

More research is needed to confirm the findings and to investigate whether lower doses of marijuana may have similar benefits with fewer adverse effects, said study researcher Dr. Jody Corey-Bloom, professor of neurosciences and director of the Multiple Sclerosis Center at the University of California, San Diego.

The study is published today (May 14) in the Canadian Medical Association Journal.

Improved symptoms

Previous studies have suggested marijuana use may have benefits for MS patients, but most have investigated oral forms of the drug, including mouth sprays and capsules. In addition, most studies have asked patients to report changes in their symptoms, rather than having a researcher objectively assess them…

Participants were randomly assigned to receive treatment with a marijuana cigarette or a placebo cigarette, which did not contain delta-9-tetrahydrocannabinol (THC), the active ingredient of marijuana. Participants smoked a marijuana cigarette once a day for three consecutive days under the supervision of a researcher. Eleven days later, participants repeated the procedure, but this time, they switched treatment groups so that everyone received the marijuana cigarette and placebo at some point in the study. On average, participants smoked four puffs of their cigarettes at each session.

Shortly after each treatment session, the researchers assessed participants with a test specifically designed to measure spasticity.

After smoking marijuana, participants experienced a 30 percent reduction in spasticity, compared with when they smoked the placebo cigarette, Corey-Bloom said.”

More: http://www.nbcnews.com/health/pot-smoking-may-help-relieve-symptoms-ms-771076

Cannabis eases multiple sclerosis (MS) stiffness per study published in neurology journal

“The trial, led by John Peter Zajicek of Britain’s Clinical Neurology Research Group, says standardized doses of cannabis extract can be useful in easing pain and spasms in this disease.”


	Use of cannabis extract helps ease painful muscle stiffness among patients with multiple sclerosis (MS), according to a large new trial.

“Use of cannabis extract helps ease painful muscle stiffness among patients with multiple sclerosis (MS), according to a large trial published on Tuesday in the Journal of Neurology, Neurosurgery and Psychiatry…”

http://www.nydailynews.com/life-style/health/cannabis-eases-multiple-sclerosis-ms-stiffness-study-article-1.1179450

 

Aylsham multiple sclerosis sufferer says cannabis-based drug ‘changed my life’

“A new cannabis-based licensed drug has transformed the life of multiple sclerosis (MS) sufferer Teresa Pointer from Aylsham.”

Teresa Pointer, from Aylsham, whose MS has been helped by using a new drug based on cannabis plant extracts.
PHOTO: ANTONY KELLY

“Mrs Pointer, 42, spotted an advertisement in the EDP eight years ago, asking people to take part in treatment trials at the James Paget University Hospital, Gorleston, and she has not looked back.

Today, thanks to two daily sprays of Sativex into her mouth, Mrs Pointer can sleep at night, walk for longer – and she has got her sense of humour back.

“I got in touch with Dr Willy Notcutt at the James Paget and then started on a clinical trial of Sativex. It was the best decision I’ve ever made and it’s done so much for me. It really has given me my life back,” said Mrs Pointer, who lives with her husband and two daughters in Hungate Street.

She was diagnosed in 2004 with MS, a disease which affects nerves in the brain and spinal cord.

An increase in muscle tone, or “spasticity”, is a common symptom, causing involuntary muscle spasms, immobility, disturbed sleep, and pain.

Although MS is incurable, treatments and specialists can help sufferers manage their symptoms.

Within two weeks of starting the trial, Mrs Pointer, whose health problems forced her to retire from her job as an assistant cook at Aylsham’s Bure Valley School, began to notice an improvement.

“It doesn’t take any of the symptoms away but it relieves them,” she said. The drug relaxed her muscles, easing the pain, discomfort and spasms when her legs would “try and jump off the bed”, which stopped her sleeping.

“I had been getting so tetchy through lack of sleep. I was snappy and angry all the time. But, because it helped me sleep, I could laugh and smile again. I found the funnier side of life which I thought I’d lost forever.”

At a later point in the double-blind trial, which involved 18 local patients, Mrs Pointer, without her knowledge or that of the medical team, was given a placebo instead of Sativex. Her symptoms soon returned and she could not sleep.

After discussions with specialists, she was put back on the drug. “That night I slept like a baby again. The contrast was so stark,” she said.

Mrs Pointer said she had no previous experience of cannabis but Sativex only relaxed muscles, it did not generate the “high” sought by recreational drug users.

She also believes that, without the drug, she would be using her wheelchair far more often than she does at present as it relaxes her leg muscles enough to allow her to walk greater distances.

Dr Notcutt, research and development director at the James Paget, said Mrs Pointer’s participation in the trial had been invaluable.

He added: “The results of these studies are being used all across the world as doctors and others look at the potential value of this medicine. Teresa and others like her locally have been pioneers in a therapy that has a huge potential in many different areas. Without more volunteers to help us explore, medical research will only make very slow progress.”

■ Around 100,000 people in the UK have MS. It is normally diagnosed in people between the ages of 20 and 40, and affects almost three times as many women as men.

■ Sativex, in the form of a mouth spray, contains the principal extracts delta-9-tetrahydrocannabinol and cannabidiol – found in the leaf and flower of the cannabis plant, and is the first cannabinoid preparation to be licensed in the UK for use in the treatment of muscle spasms in MS.”

http://www.eveningnews24.co.uk/mobile/news/aylsham_multiple_sclerosis_sufferer_says_cannabis_based_drug_changed_my_life_1_2276182

Medical Cannabis Treatment for Cancer and HIV/AIDS ?

“Benefits of Medical Cannabis”

medical marijuana

“Today, there are at least 17 states, including the District of Colombia, where cannabis is legal. Ohio, South Carolina, Colorado, New Jersey, California, and Michigan are just a few states that garnered strong support in the legalization of  medical cannabis. In Illinois, a bill legalizing the use of  cannabis needed the signature of Gov Pat Quinn. The legislation was approved by House and Senate, permitting doctors to prescribe cannabis for cancer and patients with HIV/AIDS and other diseases…

There is now quantifiable evidence that cannabis is beneficial in treating many disorders…

Moreover, the Medical Cannabis Research and the University of California found out that cannabis can treat HIV/AIDS and multiple sclerosis symptoms. It can even benefit cancer patients to mitigate the unpleasant side effects of chemotherapy or as an alternative treatment for cervical cancer, breast cancer, prostate cancer, lung cancer, colorectal cancer, brain cancer, and leukemia.”

More: http://guardianlv.com/2013/05/medical-cannabis-treatment-for-cancer-and-hivaids/

News: Can marijuana treat the symptoms of Crohn’s Disease?

“A new study, published in the journal Clinical Gastroenterology and Hepatology, suggests that cannabis could help relieve symptoms of Crohn’s Disease, a lifelong chronic illness that causes abdominal pain, cramping, diarrhea, nausea, vomiting, weight loss and lack of energy.”

News: Can marijuana treat the symptoms of Crohn

“That’s good news for sufferers, especially considering there is currently no cure.

Researchers studied 21 patients with Crohn’s Disease. Participants were randomly assigned to one of two groups: The first group was given cannabis cigarettes twice a day, the second group was given a  placebo containing cannabis flowers from which the THC had been removed.

“A short course (8 week) of THC-rich cannabis produced significant clinical, steroid-free benefits to 11 patients with active CD, compared to placebo, without side effects,” the study’s authors wrote.

The most promising part?

“Complete remission was achieved by 5/11 subjects in the cannabis group.”

Crohn’s patients aren’t the only ones who can benefit from marijuana’s medical properties, according to new research.

A recent study published in the American Journal of Medicine, suggests that marijuana can lower the risk of diabetes as well.

Marijuana users have lower fasting insulin levels, Murray Mittleman, associate professor of medicine at Harvard Medical School and the lead author of the study told Time Healthland. They are “less resistant to the insulin produced by their body to maintain a normal blood sugar level,”he says.

According to Health Canada, medical marijuana can also be used to manage symptoms like severe pain, cachexia, anorexia, weight loss, and severe nausea from cancer; arthritis pain; seizures from epilepsy; and pain and muscle spasms from spinal cord injuries and multiple sclerosis.”

More:http://www.besthealthmag.ca/blog/post/news-can-marijuana-cure-crohns-disease

Cannabis May Offer Alzheimer’s Hope, Study Says

“Marijuana compounds offer an alternative approach for treating the neurodegeneration associated with Alzheimer’s disease (AD)…

Investigators at the Trinity College, Institute for Neuroscience, in Dublin report that cannabinoids have been shown to protect neurons from the deleterious effects of amyloid plaque – the primary pathological hallmark of Alzheimer’s. Cannabinoids also demonstrate a propensity to reduce oxidative stress and inflammation, while also promoting neurogenesis (the birth of new neuronal cells), authors report.

Authors write: “In recent years the proclivity of cannabinoids to exert a neuroprotective influence has received substantial interest as a means to mitigate the symptoms of neurodegenerative conditions. … [C]annabinoids offer a multi-faceted approach for the treatment of Alzheimer’s disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain’s intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. … Manipulation of the cannabinoid pathway offers a pharmacological approach for the treatment of AD that may be efficacious than current treatment regimens.”

Preclinical studies have demonstrated that cannabinoids can delay disease progression in animal models of several neurodegenerative diseases, including multiple sclerosis and amyotrophic lateral sclerosis (Lou Gehrig’s disease).”-

Paul Armentano, NORML  http://norml.org/news/2007/09/20/cannabis-may-offer-alzheimers-hope-study-says

Full text of the study, “Alzheimer’s disease; taking the edge off with cannabinoids?” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2190031/

Effects of cannabinoids on the immune system and central nervous system: therapeutic implications.

“Cannabinoids possess immunomodulatory activity, are neuroprotective in vivo and in vitro and can modify the production of inflammatory mediators… Cannabinoid-induced immunosuppression may have implications for the treatment of neurological disorders that are associated with excess immunological activity, such as multiple sclerosis and Alzheimer’s disease. There is anecdotal evidence that cannabis use improves the symptoms of multiple sclerosis, and studies with animal models are beginning to provide evidence for the mechanism of such effects. The development of nonpsychotropic cannabinoid analogues and modulators of the metabolism of endogenous cannabinoid ligands may lead to novel approaches to the treatment of neurodegenerative disorders.”

http://www.ncbi.nlm.nih.gov/pubmed/18031185

The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis.

Abstract

“Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are chronic diseases of the central nervous system (CNS), featured by a complex interplay between inflammation and neurodegeneration. Increasing evidence supports the involvement of the endocannabinoid system (ECS) in both inflammatory and neurodegenerative processes typical of these pathological conditions. Exogenous or endogenous cannabinoids regulate the function of immune system by limiting immune response. On the other hand, by preventing excitotoxic damage, cannabinoids protect neuronal integrity and function. Of note, the ECS not only plays a role as modulator of disease processes, but it can also be disrupted by the same diseases. Agents modulating cannabinoid receptors or endocannabinoid tone provide promising therapeutic opportunities in the treatment of inflammatory neurodegenerative disorders of the CNS.”

http://www.ncbi.nlm.nih.gov/pubmed/20353778

The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.

“Alterations of the endocannabinoid system (ECS) have been recently implicated in a number of neuroinflammatory and neurodegenerative conditions so that the pharmacological modulation of cannabinoid (CB) receptors and/or of the enzymes controlling synthesis, transport, and degradation of these substances has emerged as a valuable option to treat neurological diseases.

Here, we describe the current knowledge concerning the rearrangement of ECS in a primarily inflammatory disorder of the central nervous system such as multiple sclerosis (MS), and in a primarily degenerative condition such as amyotrophic lateral sclerosis (ALS).

 Furthermore, the data supporting a therapeutic role of agents modulating CB receptors or endocannabinoid tone in these disorders will also be reviewed. Complex changes of ECS take place in both diseases, influencing crucial aspects of their pathophysiology and clinical manifestations. Neuroinflammation, microglial activation, oxidative stress, and excitotoxicity are variably combined in MS and in ALS and can be modulated by endocannabinoids or by drugs targeting the ECS.”

http://www.ncbi.nlm.nih.gov/pubmed/17678961